No retraction, correction or concern found when last checked on Oct 27, 2026.

The Neurovascular Unit Dysfunction in Alzheimer’s Disease

Luis O. Soto-Rojas, Mar Pacheco-Herrero, Paola A. Martínez-Gómez and 7 more

International Journal of Molecular Sciences · 2021 · Review · CC BY

doi:10.3390/ijms22042022

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease worldwide. Histopathologically, AD presents with two hallmarks: neurofibrillary tangles (NFTs), and aggregates of amyloid β peptide (Aβ) both in the brain parenchyma as neuritic plaques, and around blood vessels as cerebral amyloid angiopathy (CAA). According to the vascular hypothesis of AD, vascular risk factors can result in dysregulation of the neurovascular unit (NVU) and hypoxia. Hypoxia may reduce Aβ clearance from the brain and increase its production, leading to both parenchymal and vascular accumulation of Aβ. An increase in Aβ amplifies neuronal dysfunction, NFT formation, and accelerates neurodegeneration, resulting in dementia. In recent decades, therapeutic approaches have attempted to decrease the levels of abnormal Aβ or tau levels in the AD brain. However, several of these approaches have either been associated with an inappropriate immune response triggering inflammation, or have failed to improve cognition. Here, we review the pathogenesis and potential therapeutic targets associated with dysfunction of the NVU in AD.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 27, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1The neurovascular unit (NVU) is defined as a complex functional and anatomical structure composed of: (a) neurons and interneurons, (b) glial cells such as microglia, astrocytes, and oligodendrocytes, (c) vascular cells such as endothelial cells, pericytes, and smooth muscle cells (SMCs), and (d) a basal lamina formed by brain endothelial cells and extracellular matrix (Figure 1). The NVU components are intimately linked to each other, enabling an efficient system for cerebral blood flow (CBF), maintenance of neuronal metabolic activity, and an effective blood-brain barrier (BBB). The BBB is a specialized structure in the cerebral vasculature formed by astrocytes, pericytes, and specialized junctions such as tight-junctions (TJs) and adherent-junctions (AJs) of endothelial cells. The BBB serves to limit the entry of pathogens, toxic agents, and blood cells into the brain parenchyma. The junctional components of the NVU are made by gap junctions and adhesion molecules such as integrins and cadherins. This interplay facilitates the influx/efflux of Ca2+, K+, and the neuromodulatory action of ATP. Each NVU component plays an active and specific role in maintaining the dynamic linkages reciprocally under physiological conditions. Dysregulation of the NVU and BBB are critical pathophysiological events in neurodegenerative diseases, including Alzheimer’s disease (AD).

2AD is one of the most important neurodegenerative disorders worldwide and the leading cause of cognitive and functional decline in the elderly. The classic neuropathological hallmarks of AD involve aggregates of tau and amyloid β-peptides (Aβ). Neurofibrillary tangles (NFTs) and hyperphosphorylated tau accumulate intracellularly and are typically accompanied by neuronal loss. The second hallmark is the presence of amyloid β-peptide (Aβ) deposits in the brain parenchyma and around cerebral blood vessels as neuritic plaques (NPs) and cerebral amyloid angiopathy (CAA), respectively. CAA is characterized by Aβ deposition within the walls of cortical and leptomeningeal arteries and veins, which lead to NVU dysfunction. CAA is universally found in AD brains and has been linked to neuroinflammation, chronic hypoperfusion, ischemia, and loss of the blood vessel wall integrity and hemorrhage.

3In this study, we review the relationship between the NVU and BBB dysregulation and AD pathology. Furthermore, possible therapeutic targets aimed at preventing or restoring NVU in AD are discussed.

2. Cellular and Structural Components of the NVU Along the Cerebrovascular Tree

4An extensive system of arteries, arterioles, and capillaries, delivers oxygenated blood and nutrients to the brain. The pial arteries derived from arteries go along the brain surface and penetrate the parenchyma, branching into arterioles and capillaries. The cellular NVU composition changes along the cerebrovascular tree (Figure 1a):Pial arteries consist of multiple layers of SMCs, separated from the endothelium by a notable elastic lamina (Figure 1b), and innervated by nerve fibers formed from sensory and peripheral autonomic ganglia. The pial arteries penetrating the brain are surrounded by the subarachnoid space (SAS; Figure 1b). Traditionally, the pial arteries have been associated with CBF and neuronal homeostasis.Penetrating arterioles have several thin SMC layers that become a single layer (Figure 1c). The density of perivascular nerves is low at this level, and the elastic lamina becomes less prominent. The perivascular space (also known as “Virchow-Robin space”) is delimited by the astrocytic end-foot (glia limitans) and the vascular basement membrane. It comprises different cell types, including perivascular macrophages (PVMs), pial cells, Mato cells and mast cells, and collagen and nerve fibers (Figure 1c). The perivascular space is an exchange pathway for the glymphatic system. The glymphatic system has been defined as a network of perivascular pathways that favors the exchange of both solutes and liquids between the cerebrospinal fluid (CSF) and the interstitial compartments, promoting clearance of metabolites, proteins, and debris from the brain interstitium. This clearance depends mainly on the aquaporin-4 water channels (AQP4), found in astrocytic end-feet. It has been demonstrated that the pial and penetrating arterioles can regulate arterial tone by the extrinsic and intrinsic innervations, respectively.The intraparenchymal arterioles are formed when the arterioles invade deeper into the brain. Here, the glial limitans and the vascular basement membrane fuse, eliminating the Virchow-Robin space. These arterioles have a single layer of SMCs, lack perivascular nerves, and are encapsulated by the astrocytic end-feet (Figure 1d). Endothelial cells extend their protrusions to SMCs and connect through gap junctions. They are related to functional hyperemia, which ensures a rapid increase in the CBF rate to activated brain structures.Capillaries are the smallest vessels in the brain and exchange molecules between blood and brain across the BBB. Pericytes replace the SMCs, and mural cells are immersed in the endothelial basement membrane (Figure 1e). The border of the capillaries is enveloped by astrocytic end-feet, and the neural processes can be adjacent to the capillary basal lamina (Figure 1e). Pericytes and endothelial cells make direct interdigitated contacts where cytoplasmic protrusions (pegs) of one cell type insert into the opposing cell membrane (socket) of the other cell type.

5Pial arteries consist of multiple layers of SMCs, separated from the endothelium by a notable elastic lamina (Figure 1b), and innervated by nerve fibers formed from sensory and peripheral autonomic ganglia. The pial arteries penetrating the brain are surrounded by the subarachnoid space (SAS; Figure 1b). Traditionally, the pial arteries have been associated with CBF and neuronal homeostasis.

6Penetrating arterioles have several thin SMC layers that become a single layer (Figure 1c). The density of perivascular nerves is low at this level, and the elastic lamina becomes less prominent. The perivascular space (also known as “Virchow-Robin space”) is delimited by the astrocytic end-foot (glia limitans) and the vascular basement membrane. It comprises different cell types, including perivascular macrophages (PVMs), pial cells, Mato cells and mast cells, and collagen and nerve fibers (Figure 1c). The perivascular space is an exchange pathway for the glymphatic system. The glymphatic system has been defined as a network of perivascular pathways that favors the exchange of both solutes and liquids between the cerebrospinal fluid (CSF) and the interstitial compartments, promoting clearance of metabolites, proteins, and debris from the brain interstitium. This clearance depends mainly on the aquaporin-4 water channels (AQP4), found in astrocytic end-feet. It has been demonstrated that the pial and penetrating arterioles can regulate arterial tone by the extrinsic and intrinsic innervations, respectively.

7The intraparenchymal arterioles are formed when the arterioles invade deeper into the brain. Here, the glial limitans and the vascular basement membrane fuse, eliminating the Virchow-Robin space. These arterioles have a single layer of SMCs, lack perivascular nerves, and are encapsulated by the astrocytic end-feet (Figure 1d). Endothelial cells extend their protrusions to SMCs and connect through gap junctions. They are related to functional hyperemia, which ensures a rapid increase in the CBF rate to activated brain structures.

8Capillaries are the smallest vessels in the brain and exchange molecules between blood and brain across the BBB. Pericytes replace the SMCs, and mural cells are immersed in the endothelial basement membrane (Figure 1e). The border of the capillaries is enveloped by astrocytic end-feet, and the neural processes can be adjacent to the capillary basal lamina (Figure 1e). Pericytes and endothelial cells make direct interdigitated contacts where cytoplasmic protrusions (pegs) of one cell type insert into the opposing cell membrane (socket) of the other cell type.

3. The Physiological Characteristics of the Blood-Brain Barrier (BBB)

9The endothelial cells that make up the brain capillaries are tightly sealed and act as a barrier, referred to as the “blood-brain barrier” (BBB). The BBB is a specialized brain endothelial composition of the neurovascular system that is completely differentiated. Together with astrocytic end-feet, pericytes, and microglia, the BBB separates the circulating blood components from neurons (Figure 1e and Figure 2a).

10The nearness of the different cell types with one another in the NVU allows for an effective paracrine regulation, the maintenance of the BBB, and the normal functioning of the central nervous system (CNS), such as synaptic transmission and remodeling, neurogenesis, and angiogenesis in the adult brain. The cell-to-cell hermetic contact confers to the BBB the properties of low paracellular and transcellular permeability and high transendothelial electrical resistance.

11The firmly sealed endothelium limits the entry of most blood-derived particles into the brain unless they possess receptors or carriers (glucose, hormones, amino acids, and nucleotides) to be transported across the BBB. The concentration gradient is the most considerable factor for carrier-mediated transport across the BBB and is preferentially influenced by the affinity, size, and physiochemical properties of each specific molecule. The BBB excludes typically free exchange of solutes between blood-brain and brain-blood. One exception is that of small lipid-soluble molecules <400 Da, which can cross the BBB via lipid-mediated diffusion, adsorptive endocytosis, and receptor-mediated endocytosis. On the other hand, transendothelial passive diffusion enables the small influx of lipophilic and nonpolar molecules into brains across the lipid bilayer of endothelial cells.

12Endothelial cells are typically connected at a junctional complex by the tight-junctions (TJs) and adherent-junctions (AJs) (Figure 2a). The TJs provide low paracellular permeability, high electrical resistance, and binding to the cytoskeleton. Claudin (Figure 2a), a transmembrane protein of 207–305 amino acids, is the main structural component of the TJs. Different claudin isoforms are expressed in brain endothelial cells, such as claudin-1, -3, -5, and -12; claudin-5 being the most highly expressed in these cells. Occludin (Figure 2a), another tetraspan transmembrane protein of 522 amino acids of TJs, regulates BBB integrity and permeability. The transmembrane TJ proteins are linked to the actin cytoskeleton through the zonula occludens-1 (ZO-1; Figure 2a), a membrane-associated protein. Together, these complex of TJ proteins decrease the paracellular diffusion and limit transcellular activity.

13The AJs are typically found intermingled with the TJs and contribute to regulating the BBB permeability and leukocyte extravasation. Vascular endothelial (VE)-cadherin is an endothelial-specific integral membrane protein, connected to the cytoskeleton via catenins (Figure 2a). The localization and expression of β-catenin, α-catenin, and p120cas, are essential for the functionality of AJs. Neutrophils and lymphocytes can ingress from the blood into the brain regulated by BBB and low levels of leukocyte adhesion molecules (LAMs). Therefore, this property may prevent access of immune cells from blood to the brain, affording immunologic benefit in the CNS.

14BBB integrity is essential for controlling the molecular composition of brain interstitial fluid (ISF), which is indispensable for correct information processing, synaptic operating, functioning, and neuronal connectivity. BBB breakdown could trigger an increase in vascular permeability, reduce CBF and impaired hemodynamic responses. Therefore, BBB dysfunction could facilitate the entry of toxic blood-derived molecules and cells and trigger an immune response associated with neuroinflammation, which ends in degeneration of the NVU (Figure 2b and Figure 3 steps 2c, 3 and 4).

4.1. Bidirectional Pathological Association between Tau and the NVU and BBB

15Tau is a microtubule-associated protein that stabilizes microtubules (Figure 2a), polymers of tubulin that form part of the cytoskeleton and provide structure to eukaryotic cells. Tau protein has also been associated with cell signaling, regulation of genomic stability, and synaptic plasticity. Among numerous post-translational modifications, tau is subject to phosphorylation and truncation in AD brain tissue (Figure 2b). Both abnormal changes have been implicated in the accumulation of abnormal tau polymers and paired helical filaments (PHFs). Pathological tau protein leads to microtubule disintegration and NFT formation (Figure 2b). Evidence suggests that dysfunction of the NVU and BBB is triggered by Aβ vascular deposits. However, it has been noted that the presence of pathological tau has been observed as puncta in perivascular spaces in sporadic AD brains. Therefore, dysfunction of the NVU and BBB could trigger tau hyperphosphorylation and, vice versa, tau pathology could induce the NVU/BBB alteration (Figure 2b).

16In a transgenic mouse that overexpresses human tau protein carrying the P301L mutation, tau accumulates and eventually leads to BBB disruption. However, the mechanisms by which modified tau could trigger the BBB breakdown are not yet understood. It has been demonstrated that human truncated tau upregulated mRNA expression for several MAPKs (JNK1, p38b, ERK1) and transcription factors (c-Jun, c-Fos, NFkB1, NFkB2). Transcription of pro-inflammatory genes, ultimately leading to the release of proinflammatory cytokines is also increased (Figure 2b). The neuroinflammatory environment has been closely related to BBB dysfunction by increasing permeability, promoting structural changes in brain capillaries, and enhancing the migration of immune cells (Figure 2b). It has also been suggested that tau-induced activation of glial cells raises the expression of endothelial adhesion molecules and the transport of leukocytes across the BBB, perpetuating the neuroinflammatory environment and exacerbating AD pathology (Figure 2b).

17On the other hand, dysfunction of the NVU and BBB could lead to tau pathology. Accumulation of extracellular Aβ induces astrocytes and microglia activation, and the subsequent release of proinflammatory molecules. This neuroinflammatory environment could promote BBB damage and accelerate the development of tau phosphorylation and NFT formation (Figure 2b). BBB dysfunction can induce pathological tau, and abnormal tau can produce BBB alteration, thus causing a feedback loop (Figure 2b).

4.2. CAA Acts as a Trigger for Dysfunction of the NVU

18Dysfunction of the NVU and BBB is closely associated with CAA and may exacerbate AD. CAA is distinguished by the accumulation of Aβ fibrils in the walls of capillaries and small to medium-sized arterial blood vessels caliber of CNS parenchyma and leptomeninges. Besides, CAA is strongly associated with spontaneous intracerebral hemorrhage in older adults and a significant risk factor for age-related cognitive decline. CAA has two presentations: sporadic and hereditary. The sporadic CAA is associated with aging and is a common feature of AD, the amyloid is predominantly composed of the Aβ protein. For hereditary CAA, the nature of the amyloid deposits is associated with the respective underlying mutation in the amyloid precursor protein (APP) gene.

19Mutations in the APP gene, generally causing single amino acid substitutions, are the triggers of autosomal dominant CAA and early-onset AD. The E693Q (Dutch), L705V (Piedmont), and E693K (Italian) mutations are characterized by severe amyloid angiopathy without NFTs or NPs. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), is caused by the E693Q mutation, which causes Aβ aggregation in cerebral and cerebellar meningeal arteries and cerebrocortical arterioles. The histopathological features of HCHWA-D are loss of SMCs, wall thickening, perivascular reactive astrocytes, activated microglia, degenerating neurites, and gemistocytic astrocytes linked to BBB dysfunction. These histopathological changes and cognitive deterioration reflect severe vasculopathic changes and severe changes in cellular and structural components of the NVU.

4.3.1. Perivascular Microglial Activation

20Microglia are resident innate immune cells of the CNS. Under physiological conditions, microglia cells are in a “resting or quiescent state” characterized by small-bodied cells with long and thin branches. On the contrary, in pathological conditions, they acquire an “amoeboid or activated state,” they swell and retract their processes and are associated with phagocytic activity and pro-inflammatory cytokine release (Figure 3, step 1). Furthermore, it has been proposed that microglia are the first cells to degrade both soluble and fibrillar Aβ aggregates (Figure 3, step 1) via receptor interaction (Table 1). This interaction could lead to the activation and production of several toxic molecules, and finally, alter the BBB/NVU (Figure 3).

4.3.2. Astrocytic End-Foot Dysfunction

21The astrocytic end-foot contributes to arteriolar tone by regulating a constant prostaglandin-E2 (PGE2) flow (Figure 3, step 2a) because of the intracellular Ca2+ fluctuations. Several astrocytic receptors can interact with the Aβ peptide (Table 1), triggering a neuroinflammatory environment and an alteration in the NVU/BBB (Figure 3, step 2a). During the progression of AD, astrocytic end-foot dysfunction could exacerbate the extracellular and vascular accumulation of Aβ by altering its clearance along with the ISF drainage through the glymphatic system. It favors the CSF flow along with the arterial perivascular spaces, and from there to the brain interstitium through the AQP4. Finally, it removes solutes from the neuropil into the cervical and meningeal lymphatic drainage vessels. Dysfunction of the glymphatic system has been observed in AD animal models, most likely because of the dysfunction of AQP4, which increases both Aβ plaque formation and cognitive deficits. In humans, genetic variation in AQP4 affects Aβ burden, and AD patients with specific AQP4 single nucleotide polymorphism exhibit a rapidly progressive cognitive decline. Histopathological AD brain studies have demonstrated that the loss of perivascular AQP4 localization predicts disease status. Therefore, a dysfunction of the lymphatic system can cause an impairment of Aβ efflux and its accumulation on brain vessels and dysfunction of the NVU (Figure 3, step 2a).

4.3.3. Pericyte Degeneration

22Pericytes are essential for regulating the physical and functional BBB properties through proper signaling with brain endothelial cells (BECs). Both platelet-derived growth factor subunit B (PDGF-B) and platelet-derived growth factor receptor-β (PDGFRβ) are closely involved in signaling in these pericytes/BECs. Defective signaling leads to BBB disruption, a decrease in CBF, and hypoxia, which in turn triggers neuronal and synaptic dysfunction (Figure 3, step 2b). These events may further exacerbate both parenchymal and vascular Aβ accumulation. The interaction between Aβ and the pericytes receptors (Table 1) triggers endothelin-1 release from pericytes, resulting in pericyte contraction and subsequently capillary constriction (Figure 3, step 2b). There is an association between the accumulation of blood-derived proteins (thrombin, fibrinogen, plasminogen, immunoglobulin G, and albumin) and the pericyte degeneration (Figure 3, step 2b). Thus, pericyte degeneration can cause a decrease in CBF, leading to neurodegeneration.

4.3.4. Endothelial Cell Degeneration and BBB Breakdown

23Postmortem studies in AD brains have shown several vascular alterations, including fragmented vessels, string vessels, irregularities in the capillary surface, changes in vessel diameter, thickening, vacuolization, and local rupture of the capillary basement membrane, associated with vascular Aβ accumulation. Also, data from postmortem human brains have demonstrated a substantial reduction in volume associated with CAA. This event might be partly explained because TJs proteins are substrates of vascular-associated matrix metalloproteinase (MMP) activity (Figure 3, step 2c). Likewise, low levels of mesenchyme homeobox gene 2 (MEOX2) (Figure 3, step 2c) have been reported in AD brains. MEOX2 has been shown to mediate aberrant angiogenic responses, lead to premature capillary pruning, and trigger cerebral hypoperfusion and vascular inflammation.

4.3.5. Neuronal Cell Death Mechanisms

24In AD, cerebral perfusion is impaired because of the compromised ISF drainage due to the destruction of perivascular space and accumulation of Aβ. Aβ can bind to specific neuronal receptors (Table 1) and cause toxicity, induced mainly by oxidative stress. Oligemia can trigger neuronal dysfunction, altering proteins required for synaptic plasticity, and favoring anaerobic brain metabolism. Oligemia can also decrease the generation of ATP, necessary for maintaining the Na+, K+-ATPase pump and the required action potentials for normal neuronal excitability. It has been shown that transient depletion of oxygen and glucose loss can cause neuronal excitotoxicity and subsequent neuronal death. Oxygen reductions can alter pH and water-electrolyte balance, leading to edema, white matter lesions, and accumulation of both glutamate and Aβ in the brain. A decrease in the levels of GLUT1 (glucose transporter in neurons) and GLUT3 (glucose transporter in BBB) in AD patients suggests that these may contribute to impaired glucose uptake and metabolism in the brain, which could trigger the phosphorylation of tau protein (Figure 3, step 4).

4.4. The Two-Hit Vascular Hypothesis and Dysfunction of the NVU

25According to the two-hit vascular hypothesis of AD, there exists a vascular contribution (hit one) that followed the effect of Aβ accumulation (hit two). Vascular risk factors, such as diabetes or hypertension, could lead to NVU/BBB dysregulation and, subsequently, CBF reduction (oligemia), initiating a cascade of events that precedes dementia. This defective Aβ clearance has been postulated to trigger increased cerebrovascular Aβ production and aggregation. There are several receptors in the endothelial cells that promote Aβ clearance (Table 2). The primary receptor that regulates Aβ transcytosis is LRP1 (Figure 3, step 2c; Table 2). In AD, there are significant reductions in LRP1 and SMCs that correlate with an increase in cerebrovascular Aβ. High levels of serum response factor (SRF) and myocardin in SMCs lead to elevated expression of the sterol response element-binding protein 2 (SREBP2), an important transcriptional LRP1 suppressor, triggering LRP1 depletion and reducing Aβ clearance through the BBB (Figure 3, step 2b). In contrast, RAGE is the receptor for the influx of Aβ through the BBB that transports it from the blood to the brain (Figure 3, step 2c; Table 2), and an increased expression of RAGE in the brain endothelium of AD patients has been reported (Figure 3, step 2c). Subsequently, oligemia promotes the CBF loss (Figure 3, step3), resulting in endothelial cell death. Finally, the increase in Aβ accumulation (hit two) accelerates neuronal dysfunction, NFT formation, neurodegeneration, and dementia (Figure 3, step 4).

5.1. General Limitations in AD Therapy

26One of the main hurdles for developing new drugs for AD is that the BBB limits the access of substances to the brain. The endothelium, one of the main components of the BBB, acts as a physical barrier because of the TJs and AJs. Also, it possesses an enzymatic complex (CYP450, xanthine oxidase, MAO) capable of metabolizing various molecules, reducing their bioactivity in the brain. Likewise, efflux pumps (P-gp, MDR and MRP) placed on the endothelial abluminal surface can release molecules back into the peripheral circulation. In AD, the overexpression of the efflux pump may contribute to the failure of therapeutic trials. It is estimated that around 98% of small and 100% of large molecule drugs, do not cross the BBB and hence do not achieve adequate therapeutic concentrations in the brain. Most drugs are incapable of crossing the BBB due to polarity, size, or lack of endogenous transport pathways. Drug delivery systems (DDS) have emerged as an essential procedure to address these concerns. DDS can preserve molecules from degradation and carry them across membranes by hiding their chemical properties but without modifying them. Nanoparticles, as an example of DDS, serve to release drugs for prolonged periods. Nanoparticle transport by receptor-mediated endocytosis is the main procedure to transport drugs across the BBB and this therapeutic approach will be discussed in a section below.

27AD therapeutics has focused on replacing the depletion of acetylcholine levels to improve symptoms in patients. Donepezil, one of the most widely used, is an acetylcholinesterase inhibitor that crosses the BBB via the organic cation transporter. Donepezil has been shown to improve cognitive functions in patients with mild to moderate AD by enhancing the acetylcholine bioavailability. However, a major limitation for donepezil is its P-glycoprotein (P-gp)-mediated efflux. There is a threshold for its use: most patients only tolerate low doses because of its adverse cholinergic side-effects. Besides, patients at a particular phase of the disease do not respond to therapy because there is already neuronal deficit or death and hence absence of synaptic connections.

5.2. Therapeutics Associated with the Amyloidogenic Pathway

28Aβ aggregation and binding of Aβ to different receptors appears to be a characteristic hallmark of AD. Therapeutic strategies to decrease Aβ production, promote its elimination, and prevent fibrillar aggregation are being developed worldwide. These have targeted the three enzymes associated with the amyloidogenic pathways by increasing the activity of α-secretase or suppressing β- and γ-secretase (Table 2a–c). Nevertheless, therapies that modulate β- and γ-secretases have been reported to increase the risk of serious adverse events in AD patients.

29There are two types of immunotherapy directed against Aβ peptides: active (Table 2j) and passive immunization (Table 2l). While both types of immunotherapeutic approaches against Aβ peptides have shown promise in animal models, these are yet to be translated into the clinic. Typically, active immunotherapy consists of an antigen, alone or conjugated to a non-self T helper cell epitope. Active Aβ immunization produces anti-Aβ antibodies that bind to human NPs and can induce long-term antibody. It can also trigger an immune response by activation of Th2 lymphocytes. Passive immunotherapy involves the direct injection of antibodies and does not require the immune system to generate its own antibody response. This therapy has the advantage that it can be directed at a specific epitope and can be stopped if there are any adverse effects. Passive immunization can also promote Aβ clearance by either central or peripheral mechanisms. In the central mechanism, the anti-Aβ antibodies cross the BBB and bind to NPs, triggering an immune response by activating the Th2 lymphocytes. This culminates in the activation of microglial cells responsible for phagocytosis of Aβ and the reduction of amyloid deposits. In the periphery, antibodies can bind and sequester plasma Aβ. When peripheral Aβ is diminished, Aβ efflux from the brain to the bloodstream is favored, reducing the levels of Aβ in the brain. Nevertheless, passive immunization generally requires expensive humanized monoclonal antibodies and repeated injections, making it less suitable for the long-term treatment of AD than active immunization. Repeated injections of antibodies can also lead to the generation of autoantibodies that may neutralize their effect or even trigger side effects such as vasculitis and glomerulonephritis.

30Circulating antibodies, following immunization, must be able to cross the BBB to exert their cerebral effect. Few studies have analyzed the mechanisms and ability of antibodies directed against Aβ to enter the brain from the bloodstream. These studies have used IgG antibodies, that have demonstrated low permeability and brain accumulation. It has been suggested that these antibodies can cross the BBB through extracellular pathways, since most IgG antibodies have an unsaturated blood transport system to the brain, depending on these pathways to enter CNS. Furthermore, it has been proposed that a brain-to-blood efflux system could exist in the BBB for IgG antibodies.

5.3. Drugs Targeting Tau Protein

31Because pathological tau is both toxic to cells and a mediator of Aβ toxicity, targeting tau appears to be a logical therapeutic strategy for AD (Table 2f–i). Several tau aggregation inhibitors have been studied (Table 2f). Methylthioninium, the first tau aggregation inhibitor (TAI) to be discovered, was shown to reduce tau pathology and improve cognition in transgenic mouse models of AD and frontotemporal dementia (FTD). Curcumin, a natural product of the plant Curcuma longa and another TAI, has shown antioxidant and anti-inflammatory properties. However, no significant beneficial effects have been reported in AD subjects receiving curcumin.

32Tau hyperphosphorylation is observed in AD, and the degree of phosphorylation is reflected by the increased activity of protein kinases. Some kinase inhibitors (Table 2g) prevent cell death and tau phosphorylation, reduce Aβ plaque burden and memory deficits in several models. These compounds can cross the BBB. However, in clinical phases, no clinical improvements have been observed.

33The microtubule stabilizer drugs (Table 2h) have been shown to increase the numbers of microtubules and reduce tau pathology and the number of axons with abnormal morphology in tau transgenic mice. However, some of these drugs have been associated with adverse effects.

34An antibody targeting the pS396 epitope reduced pathological tau levels and affected the behavioral phenotypes in mice. A monoclonal antibody against the epitope in the tau repeat domain inhibited the trans-neuronal propagation of tau aggregation. Several other studies have looked at active and passive immunotherapy approaches in tau mouse models (Table 2i,k). AADvac1 is an active vaccine consisting of a protein carrier conjugated with a synthetic peptide corresponding to tau. The immunogenicity of AADvac1 in a phase 1 trial has led to a phase 2 trial underway to assess its efficacy in preserving cognitive function (Table 2i). Passive immunization in mouse models has been used to target both extracellular tau and tau aggregates within neurons. Further clinical trials will help establish whether this therapeutic approach is effective in AD (Table 2k).

5.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

35Epidemiologic studies have reported that long-term use of NSAIDs reduced the risk for developing AD. The fenamate NSAIDs inhibit the NLRP3 inflammasome activation and decrease microglial activation. Nevertheless, randomized controlled trials investigating the use of NSAIDs and the risk of developing AD did not reach statistical significance among AD patients and subjects without dementia (Table 2n). Therefore, the effectiveness of NSAIDs for AD treatment remains uncertain.

6. Therapeutic Strategies Focused on the NVU

36Knowledge of the pathophysiology of the NVU in AD is essential for the implementation of new treatments. Emerging therapies are focusing on promoting or maintaining neural stability by either preventing or restoring damage to the NVU.

6.1. Vasculoprotective Effects of Anti-Diabetic, Lipid-Lowering, and Anti-Hypertensive Drugs

37According to the two-hit vascular hypothesis of AD, vascular risk factors such as dyslipidemia, obesity, hypertension, and diabetes can trigger dysregulation of the NVU/BBB, leading to dementia.

38Insulin-resistance has been described in the brain of AD patients. Both insulin and insulin-like growth factor 1 (IGF-1) have multiple brain functions including energy metabolism, trophic support, and synaptic activity. Accumulating evidence suggests that insulin has beneficial effects on the NVU because it is a vasoactive modulator that regulates CBF. Decreased insulin has been associated with endothelial dysfunction, generation of ROS, and excessive free fatty acids released from the adipose tissue. Intranasal administration of insulin to the brain has proved feasible in trials with AD patients (Table 3b).

39Glucagon-like peptide 1 (GLP-1) analogs are therapeutic agents associated with insulin release and sensitization (Table 3b). The peroxisome proliferator-activated receptors (PPARs) agonists that regulate glucose and lipid metabolism have vasculoprotective and neuroprotective effects, such as regulation of oxidative stress and increasing the CBF and glucose uptake (Table 3b). Although PPARs were able to improve memory, no effect on Aβ pathology was observed in some AD models.

40Statins (Table 3b) or inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase are a group of medicines used to treat dyslipidemias, that have been shown to have a neuroprotective effect in an animal model. They can restore vascular reactivity and neurovascular coupling, and improve memory, but do not reduce amyloid pathology.

41Some antihypertensive drugs can improve NVU function (Table 3a). For example, third-generation β-blockers can improve endothelial function. Calcium channel blockers (CCBs) can have antioxidant and neuroprotective effects, improve endothelial function and vascular inflammation, and attenuate the neuronal deterioration induced by Aβ. The angiotensin receptor blocker (ARBs) and angiotensin-converting enzyme (ACE) inhibitors can improve endothelial dysfunction and vascular inflammation. Other antihypertensive drugs include selective angiotensin II type 1 receptor (AT1) blockers. In rodents, AT1 receptor blockers have potential effects on NVU, such as protecting CBF during a stroke and decreasing neuroinflammation and Aβ neurotoxicity. However, they do not affect soluble Aβ or plaque load in the brain.

6.2. Drugs for Maintenance of BBB and NVU Integrity

42Memantine, an antagonist of extrasynaptic N-methyl-d-aspartate receptors (NMDARs), is currently approved for treatment of AD alone or with acetylcholinesterase inhibitors. NMDARs are ionotropic glutamate receptors that are essential for learning and memory. An increase in NMDAR activation has been related to neuronal dysfunction. Besides, in a mouse model of permanent focal cerebral ischemia, this drug has beneficial effects on NVU because it prevents cerebral ischemia caused by glutamate excitotoxicity, decreases glial activation, and decreases MMP-9 secretion. Therefore, it is considered a drug that in addition to improving cognitive functions can also protect the NVU in AD.

43Previous studies have shown that the transforming growth factor-beta (TGF-β), basic fibroblast growth factor (b-FGF), and glial cell-derived neurotrophic factor (GDNF), can promote the BBB integrity (Table 3c).

44Proteoglycan NG2, which is a contact adhesion protein that preserves pericyte-brain endothelium interconnections, has been suggested as a possible therapeutic target to maintain correct capillary function, and possibly BBB maintenance. Also, drugs that inhibit the metalloproteins effects could keep the BBB integrity, limiting the NVU damage.

45Notably, a growing body of evidence suggests that interleukin-1β (IL-1β) contributes to BBB dysfunction. Anakinra, an IL-1β receptor antagonist, has been used successfully to treat rheumatoid arthritis and could be a therapeutic target to maintain the BBB integrity in AD (Table 3c). On the other hand, glucocorticoids such as dexamethasone could promote the BBB integrity, triggering the signaling mediated by the glucocorticoid receptor, and regulating the TJs gene expression. Future studies are required to elucidate the beneficial effects of AD.

46Multiple sclerosis treatment based on monoclonal antibodies against the α4-integrin receptor on leukocytes (Table 3c) has emerged as a promising therapeutic candidate for avoiding the peripheral immune cell migration into the CNS, reducing neuroinflammation and BBB breakdown in AD.

47Targeted inhibition of RAGE–Aβ interaction has been shown to reduce Aβ influx across the BBB, consecutively decreasing the oxidant stress and neuroinflammation environment. However, additional studies with these drugs reporting on long-term outcomes in AD models are required.

6.3. Recent Approaches for Improving the NVU

48Molecular Trojan horses (MTJs), nanotechnology, and liposomes have emerged as nano-based DDS. DDS offers several benefits for potential drug molecules. These include the ability to preserve molecules from degradation, transport them through the BBB, and conserve their physicochemical properties, and they are biodegradable, biocompatible, nontoxicity, and non-immunogenic. MTJs are non-invasive approaches for drug delivery of large molecules to the brain, using receptor-mediated transcytosis (RMT).

49During neuroinflammation, there is an active change with the regulation of pro-and anti-inflammatory signals. Microglia and astrocytes, which constitute the key elements of the NVU, are activated in several neurological diseases, among them AD. Typically, the pro-inflammatory phenotype (M1/A1) corresponds to dysfunction of the NVU. It has been suggested that activated microglia induce reactive astrocytes. Reactive astrocytes (A1) can be prompted by cytokines, such as interleukin-1 alpha (IL-1α), TNF-α, and the complement component subunit 1q (C1q), which are secreted by activated microglia (M1) both in vitro and in vivo. The inhibition of these cytokines might result in repair of the NVU and cognitive improvement in AD patients. Therefore, decoy receptors, such as the human tumor necrosis factor receptor (TNFR), have been proposed as novel therapies for neurological disorders. The human TNFR-II extracellular domain as a fusion protein with a chimeric monoclonal antibody (mAb) against the human insulin receptor (HIR) to permit BBB transport of a TNFR decoy insulin receptor has been considered one of the best candidates for RTM-based therapeutics. Human insulin mAb (HImAb) is around 900% more active and ten times more successful than any human transferrin receptor (TfR). The HIRmAb can function to transport the TNFR therapeutic decoy receptor across the BBB and provide high-affinity binding to human TNFα, suppressing the cytotoxic effects of this cytokine. These properties may be effective in the restoration of the NVU in AD brains.

50Nanotechnology is a new field offering an encouraging perspective in the therapy of various CNS disorders, among them AD, and entails the use of materials that have a dimension of between 1 and 100 nm. Nanoparticles cross the BBB, and therefore allow for certain drugs to be delivered to the brain. Human serum albumin (HSA) nanoparticles seem to be a promising therapeutic approach and would allow the administration of some drugs through the BBB. However, future research is required to assess biosecurity and effectiveness for AD.

51There is a diversity of natural compounds unable to cross the BBB. They can be administrated through nanoparticles to be effective in AD therapy due to their neuroprotective activity. These beneficial effects on the NVU could result from the inhibition of the Aβ production (by, for example, regulation of secretase activities),increasing Aβ degradation, inhibition of NFT formation, and reduction of neuroinflammation and oxidative stress. The enhancement of a biodegradable nanoparticle was demonstrated for efficient brain accumulation, protection of astrocytes from oxidative stress and mitochondrial alterations using an animal model. This nanomedicine platform has potential beneficial effects on the NVU such as modulating astrocytes to enhance their neuroprotective activities.

52Several nanoparticles have shown neuroprotective effects through drugs that modulate inflammation and apoptosis, and the neuronal signaling pathways, by down-regulating pro-inflammatory cytokines and caspase-3 activity, and up-regulating anti-inflammatory cytokines in animal models. Their administration resulted in lower mRNA expression of MMP-9, cyclo-oxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). All of these molecules are crucial elements for NVU dysfunction, and hence promising as targets for AD therapy.

53Finally, targeted nanoliposomes and nanoparticles represent a viable and promising strategy for the treatment of AD. They are biocompatible and can carry many therapeutic molecules across the BBB and into NVU cells. Interestingly, immunolabelled liposomes can potentially deliver other novel technologies, such as the mAb MTJs. Modifications of the liposome can include Aβ-targeting ligands (such as curcumin, phosphatidic acid), or retro-inverted peptides, which decrease Aβ and tau aggregation, neuroinflammation, and oxidative stress, among others. However, the nonspecific uptake of the cationic liposomes by peripheral tissues and their binding to other proteins limit their therapeutic potential. The intranasal administration of liposomes offers a direct nose-to-brain route. Liposomal encapsulation can facilitate transport across the mucosal barrier. Thus, the intranasal route provides a promising alternative for delivery across the BBB.

54Additional studies focused on designing new, safe, and effective therapeutic drugs to prevent or restore the NVU damage in AD patients are needed.

7. Conclusions and Perspective

55Pathological NVU dysfunction has emerged as an essential element in AD pathogenesis. It has been suggested that vascular amyloid deposits can alter the NVU. The dysfunction of the signaling pathways between each of the cells that make up the NVU is associated with a decrease in CBF, hypoxia, neuroinflammatory status, oxidative stress, and finally, degeneration of these cells. It suggests the need to focus on therapies to prevent or repair damage to the NVU. A significant limitation in the treatment for AD is the BBB presented by the endothelial cells. Many drugs cannot cross BBB or are metabolized, decreasing their bioactivity before reaching the brain. Recent therapeutic approaches, that are still at preclinical phases, such as molecular Trojan horses (MTJs), nanotechnology, and liposomes, have been demonstrated to be of use in getting molecules across the BBB and in restoring dysfunction of the NVU. Because the NVU comprises different cellular and structural components, it becomes a real challenge to target them as a therapeutic target. Nowadays, AD therapy has focused on the interaction of limited parts of the NVU. However, it may only be necessary to impact two of the NVU elements to create a domino effect on other components. Further research is required to better demonstrate the mechanisms involved and determine whether immunotherapies or medications aimed at treating cerebrovascular risk factors for AD are able to reduce brain pathology and improve cognitive function. In this review, we have highlighted the physiological and pathological roles of the NVU to identify where avenues for developing innovative treatments for AD may exist.

References 236

1.
Harder D.R., Zhang C., Gebremedhin D. Astrocytes function in matching blood flow to metabolic activity. News Physiol. Sci. 2002;17:27-31.
Not in our library10.1152/physiologyonline.2002.17.1.27
2.
Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178-201.
Not in our library10.1016/j.neuron.2008.01.003
3.
Abbott N.J., Friedman A. Overview and introduction: The blood-brain barrier in health and disease. Epilepsia. 2012;53:1-6.
Not in our library10.1111/j.1528-1167.2012.03696.x
4.
Armulik A., Genove G., Mae M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557-561.
Not in our library10.1038/nature09522
5.
Winkler E.A., Bell R.D., Zlokovic B.V. Central nervous system pericytes in health and disease. Nat. Neurosci. 2011;14:1398-1405.
Not in our library10.1038/nn.2946
6.
Muoio V., Persson P.B., Sendeski M.M. The neurovascular unit—Concept review. Acta Physiol. (Oxford). 2014;210:790-798.
Not in our library10.1111/apha.12250
7.
Filosa J.A. Vascular tone and neurovascular coupling: Considerations toward an improved in vitro model. Front. Neuroenerg. 2010;2:16.
Not in our library10.3389/fnene.2010.00016
8.
Fields R.D., Stevens-Graham B. New insights into neuron-glia communication. Science. 2002;298:556-562.
Not in our library10.1126/science.298.5593.556
9.
Neurovascular Unit Dysfunction and Neurodegenerative Disorders · 2020
No notice
10.
Mucke L. Neuroscience: Alzheimer’s disease. Nature. 2009;461:895-897.
Not in our library10.1038/461895a
11.
Sagare A.P., Bell R.D., Zlokovic B.V. Neurovascular defects and faulty amyloid-beta vascular clearance in Alzheimer’s disease. J. Alzheimers Dis. 2013;33:S87-S100.
Not in our library10.3233/jad-2012-129037
12.
Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease · 2017
No notice
13.
Miller D.L., Papayannopoulos I.A., Styles J., Bobin S.A., Lin Y.Y., Biemann K., Iqbal K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease. Arch. Biochem. Biophys. 1993;301:41-52.
Not in our library10.1006/abbi.1993.1112
14.
Han B.H., Zhou M.L., Abousaleh F., Brendza R.P., Dietrich H.H., Koenigsknecht-Talboo J., Cirrito J.R., Milner E., Holtzman D.M., Zipfel G.J. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: Contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J. Neurosci. 2008;28:13542-13550.
Not in our library10.1523/jneurosci.4686-08.2008
15.
Chen S.J., Tsai H.H., Tsai L.K., Tang S.C., Lee B.C., Liu H.M., Yen R.F., Jeng J.S. Advances in cerebral amyloid angiopathy imaging. Ther. Adv. Neurol. Disord. 2019;12:1-11.
Not in our library10.1177/1756286419844113
16.
Xu F., Fu Z., Dass S., Kotarba A.E., Davis J., Smith S.O., van Nostrand W.E. Cerebral vascular amyloid seeds drive amyloid beta-protein fibril assembly with a distinct anti-parallel structure. Nat. Commun. 2016;7:13527.
Not in our library10.1038/ncomms13527
17.
Kisler K., Nelson A.R., Montagne A., Zlokovic B.V. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat. Rev. Neurosci. 2017;18:419-434.
Not in our library10.1038/nrn.2017.48
18.
Hamel E. Perivascular nerves and the regulation of cerebrovascular tone. J. Appl. Physiol. 2006;100:1059-1064.
Not in our library10.1152/japplphysiol.00954.2005
19.
Sekiguchi Y., Takuwa H., Kawaguchi H., Kikuchi T., Okada E., Kanno I., Ito H., Tomita Y., Itoh Y., Suzuki N., et al. Pial arteries respond earlier than penetrating arterioles to neural activation in the somatosensory cortex in awake mice exposed to chronic hypoxia: An additional mechanism to proximal integration signaling? J. Cereb. Blood Flow Metab. 2014;34:1761-1770.
Not in our library10.1038/jcbfm.2014.140
20.
Roggendorf W., Cervos-Navarro J. Ultrastructure of arterioles in the cat brain. Cell Tissue Res. 1977;178:495-515.
Not in our library10.1007/bf00219571
21.
Zhang E.T., Inman C.B., Weller R.O. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J. Anat. 1990;170:111-123.
Not in our library
22.
Jessen N.A., Munk A.S., Lundgaard I., Nedergaard M. The glymphatic system: A beginner’s guide. Neurochem. Res. 2015;40:2583-2599.
Not in our library10.1007/s11064-015-1581-6
23.
Rangroo Thrane V., Thrane A.S., Plog B.A., Thiyagarajan M., Iliff J.J., Deane R., Nagelhus E.A., Nedergaard M. Paravascular microcirculation facilitates rapid lipid transport and astrocyte signaling in the brain. Sci. Rep. 2013;3:2582.
Not in our library10.1038/srep02582
24.
Nedergaard M., Goldman S.A. Glymphatic failure as a final common pathway to dementia. Science. 2020;370:50-56.
Not in our library10.1126/science.abb8739
25.
Braun M., Iliff J.J. The impact of neurovascular, blood-brain barrier, and glymphatic dysfunction in neurodegenerative and metabolic diseases. Int. Rev. Neurobiol. 2020;154:413-436.
Not in our library10.1016/bs.irn.2020.02.006
26.
Hotta H., Masamoto K., Uchida S., Sekiguchi Y., Takuwa H., Kawaguchi H., Shigemoto K., Sudo R., Tanishita K., Ito H., et al. Layer-specific dilation of penetrating arteries induced by stimulation of the nucleus basalis of Meynert in the mouse frontal cortex. J. Cereb. Blood Flow Metab. 2013;33:1440-1447.
Not in our library10.1038/jcbfm.2013.92
27.
Longden T.A., Hill-Eubanks D.C., Nelson M.T. Ion channel networks in the control of cerebral blood flow. J. Cereb. Blood Flow Metab. 2016;36:492-512.
Not in our library10.1177/0271678x15616138
28.
Attwell D., Buchan A.M., Charpak S., Lauritzen M., Macvicar B.A., Newman E.A. Glial and neuronal control of brain blood flow. Nature. 2010;468:232-243.
Not in our library10.1038/nature09613
29.
Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 2011;12:723-738.
Not in our library10.1038/nrn3114
30.
Damisah E.C., Hill R.A., Tong L., Murray K.N., Grutzendler J. A fluoro-Nissl dye identifies pericytes as distinct vascular mural cells during in vivo brain imaging. Nat. Neurosci. 2017;20:1023-1032.
Not in our library10.1038/nn.4564
31.
Iadecola C. The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. Neuron. 2017;96:17-42.
Not in our library10.1016/j.neuron.2017.07.030
32.
Cuevas P., Gutierrez-Diaz J.A., Reimers D., Dujovny M., Diaz F.G., Ausman J.I. Pericyte endothelial gap junctions in human cerebral capillaries. Anat. Embryol. (Berlin). 1984;170:155-159.
Not in our library10.1007/bf00319000
33.
Zhao Z., Nelson A.R., Betsholtz C., Zlokovic B.V. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1064-1078.
Not in our library10.1016/j.cell.2015.10.067
34.
Sweeney M.D., Sagare A.P., Zlokovic B.V. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat. Rev. Neurol. 2018;14:133-150.
Not in our library10.1038/nrneurol.2017.188
35.
Smith Q.R. A review of blood-brain barrier transport techniques. Methods Mol. Med. 2003;89:193-208.
Not in our library10.1385/1-59259-419-0:193
36.
Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 2007;24:1745-1758.
Not in our library10.1007/s11095-007-9374-5
37.
Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today. 2007;12:54-61.
Not in our library10.1016/j.drudis.2006.10.013
38.
Deeken J.F., Loscher W. The blood-brain barrier and cancer: Transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007;13:1663-1674.
Not in our library10.1158/1078-0432.ccr-06-2854
39.
Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005;57:173-185.
Not in our library10.1124/pr.57.2.4
40.
Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. Physiol. Rev. 2004;84:869-901.
Not in our library10.1152/physrev.00035.2003
41.
Gunzel D., Yu A.S. Claudins and the modulation of tight junction permeability. Physiol. Rev. 2013;93:525-569.
Not in our library10.1152/physrev.00019.2012
42.
Furuse M., Hirase T., Itoh M., Nagafuchi A., Yonemura S., Tsukita S., Tsukita S. Occludin: A novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993;123:1777-1788.
Not in our library10.1083/jcb.123.6.1777
43.
Itoh M., Furuse M., Morita K., Kubota K., Saitou M., Tsukita S. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J. Cell Biol. 1999;147:1351-1363.
Not in our library10.1083/jcb.147.6.1351
44.
Dejana E., Orsenigo F., Lampugnani M.G. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J. Cell Sci. 2008;121:2115-2122.
Not in our library10.1242/jcs.017897
45.
Daneman R., Prat A. The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 2015;7:a020412.
Not in our library10.1101/cshperspect.a020412
46.
Michalicova A., Banks W.A., Legath J., Kovac A. Tauopathies—focus on changes at the neurovascular unit. Curr. Alzheimer Res. 2017;14:790-801.
Not in our library10.2174/1567205014666170203143336
47.
Roles of tau protein in health and disease · 2017
No notice
48.
Novak M., Kabat J., Wischik C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament. EMBO J. 1993;12:365-370.
Not in our library10.1002/j.1460-2075.1993.tb05665.x
49.
Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Ann. N. Y. Acad. Sci. 1996;777:121-131.
Not in our library10.1111/j.1749-6632.1996.tb34410.x
50.
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau · 1997
Not checked
51.
Luna-Munoz J., Garcia-Sierra F., Falcon V., Menendez I., Chavez-Macias L., Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer’s disease. J. Alzheimers Dis. 2005;8:29-41.
Not in our library10.3233/jad-2005-8104
52.
Greenberg S.M., Bacskai B.J., Hernandez-Guillamon M., Pruzin J., Sperling R., van Veluw S.J. Cerebral amyloid angiopathy and Alzheimer disease—One peptide, two pathways. Nat. Rev. Neurol. 2020;16:30-42.
Not in our library10.1038/s41582-019-0281-2
53.
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy · 2015
No notice
54.
Traumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link · 2018
Not checked
55.
Erickson M.A., Banks W.A. Blood-brain barrier dysfunction as a cause and consequence of Alzheimer’s disease. J. Cereb. Blood Flow Metab. 2013;33:1500-1513.
Not in our library10.1038/jcbfm.2013.135
56.
Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388-405.
Not in our library10.1016/s1474-4422(15)70016-5
57.
Cai Z., Qiao P.F., Wan C.Q., Cai M., Zhou N.K., Li Q. Role of blood-brain barrier in Alzheimer’s disease. J. Alzheimers Dis. 2018;63:1223-1234.
Not in our library10.3233/jad-180098
58.
Neurovascular dysfunction in vascular dementia, Alzheimer’s and atherosclerosis · 2018
No notice
59.
Gatti L., Tinelli F., Scelzo E., Arioli F., Di Fede G., Obici L., Pantoni L., Giaccone G., Caroppo P., Parati E.A., et al. Understanding the Pathophysiology of Cerebral Amyloid Angiopathy. Int. J. Mol. Sci. 2020;21:3435.
Not in our library10.3390/ijms21103435
60.
Attems J., Jellinger K., Thal D.R., van Nostrand W. Review: Sporadic cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol. 2011;37:75-93.
Not in our library10.1111/j.1365-2990.2010.01137.x
61.
Bugiani O., Giaccone G., Rossi G., Mangieri M., Capobianco R., Morbin M., Mazzoleni G., Cupidi C., Marcon G., Giovagnoli A., et al. Hereditary cerebral hemorrhage with amyloidosis associated with the E693K mutation of APP. Arch. Neurol. 2010;67:987-995.
Not in our library10.1001/archneurol.2010.178
62.
Maat-Schieman M., Roos R., van Duinen S. Hereditary cerebral hemorrhage with amyloidosis-Dutch type. Neuropathology. 2005;25:288-297.
Not in our library10.1111/j.1440-1789.2005.00631.x
63.
Maat-Schieman M.L., Yamaguchi H., Hegeman-Kleinn I.M., Welling-Graafland C., Natte R., Roos R.A., van Duinen S.G. Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Acta Neuropathol. 2004;107:389-398.
Not in our library10.1007/s00401-004-0824-4
64.
Maat-Schieman M.L., Yamaguchi H., van Duinen S.G., Natte R., Roos R.A. Age-related plaque morphology and C-terminal heterogeneity of amyloid beta in Dutch-type hereditary cerebral hemorrhage with amyloidosis. Acta Neuropathol. 2000;99:409-419.
Not in our library10.1007/s004010051143
65.
Maat-Schieman M.L., van Duinen S.G., Rozemuller A.J., Haan J., Roos R.A. Association of vascular amyloid beta and cells of the mononuclear phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease. J. Neuropathol. Exp. Neurol. 1997;56:273-284.
Not in our library10.1097/00005072-199703000-00006
66.
Tagliavini F., Giaccone G., Bugiani O., Frangione B. Ubiquitinated neurites are associated with preamyloid and cerebral amyloid beta deposits in patients with hereditary cerebral hemorrhage with amyloidosis Dutch type. Acta Neuropathol. 1993;85:267-271.
Not in our library10.1007/bf00227721
67.
Ajami B., Bennett J.L., Krieger C., Tetzlaff W., Rossi F.M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat. Neurosci. 2007;10:1538-1543.
Not in our library10.1038/nn2014
68.
The Pathophysiological Role of Microglia in Dynamic Surveillance, Phagocytosis and Structural Remodeling of the Developing CNS · 2017
No notice
69.
Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., Freeman M.W. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 2002;277:47373-47379.
Not in our library10.1074/jbc.m208788200
70.
Fonseca M.I., Chu S., Pierce A.L., Brubaker W.D., Hauhart R.E., Mastroeni D., Clarke E.V., Rogers J., Atkinson J.P., Tenner A.J. Analysis of the putative role of CR1 in Alzheimer’s disease: Genetic association, expression and function. PLoS ONE. 2016;11:e0149792.
Not in our library10.1371/journal.pone.0149792
71.
Oliveira L.C., Kretzschmar G.C., Dos Santos A.C.M., Camargo C.M., Nisihara R.M., Farias T.D.J., Franke A., Wittig M., Schmidt E., Busch H., et al. Complement Receptor 1 (CR1, CD35) Polymorphisms and soluble CR1: A proposed anti-inflammatory role to quench the fire of “Fogo Selvagem” Pemphigus Foliaceus. Front. Immunol. 2019;10:2585.
Not in our library10.3389/fimmu.2019.02585
72.
Fu H., Liu B., Frost J.L., Hong S., Jin M., Ostaszewski B., Shankar G.M., Costantino I.M., Carroll M.C., Mayadas T.N., et al. Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Abeta by microglia. Glia. 2012;60:993-1003.
Not in our library10.1002/glia.22331
73.
Zhang D., Hu X., Qian L., Chen S.H., Zhou H., Wilson B., Miller D.S., Hong J.S. Microglial MAC1 receptor and PI3K are essential in mediating beta-amyloid peptide-induced microglial activation and subsequent neurotoxicity. J. Neuroinflamm. 2011;8:3.
Not in our library10.1186/1742-2094-8-3
74.
Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010;11:155-161.
Not in our library10.1038/ni.1836
75.
Reed-Geaghan E.G., Savage J.C., Hise A.G., Landreth G.E. CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J. Neurosci. 2009;29:11982-11992.
Not in our library10.1523/jneurosci.3158-09.2009
76.
An X.Q., Xi W., Gu C.Y., Huang X. Complement protein C5a enhances the beta-amyloid-induced neuro-inflammatory response in microglia in Alzheimer’s disease. Med. Sci. (Paris). 2018;34:116-120.
Not in our library10.1051/medsci/201834f120
77.
Ager R.R., Fonseca M.I., Chu S.H., Sanderson S.D., Taylor S.M., Woodruff T.M., Tenner A.J. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer’s disease. J. Neurochem. 2010;113:389-401.
Not in our library10.1111/j.1471-4159.2010.06595.x
78.
El Khoury J., Hickman S.E., Thomas C.A., Cao L., Silverstein S.C., Loike J.D. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716-719.
Not in our library10.1038/382716a0
79.
Yang C.N., Shiao Y.J., Shie F.S., Guo B.S., Chen P.H., Cho C.Y., Chen Y.J., Huang F.L., Tsay H.J. Mechanism mediating oligomeric Abeta clearance by naive primary microglia. Neurobiol. Dis. 2011;42:221-230.
Not in our library10.1016/j.nbd.2011.01.005
80.
Ganote C.E., Sims M.A. Parallel temperature dependence of contracture-associated enzyme release due to anoxia, 2,4-dinitrophenol (DNP), or caffeine and the calcium paradox. Am. J. Pathol. 1984;116:94-106.
Not in our library
81.
Marshall R.J. Bayesian analysis of case-control studies. Stat. Med. 1988;7:1223-1230.
Not in our library10.1002/sim.4780071203
82.
Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 2003;9:907-913.
Not in our library10.1038/nm890
83.
Ni R., Marutle A., Nordberg A. Modulation of alpha7 nicotinic acetylcholine receptor and fibrillar amyloid-beta interactions in Alzheimer’s disease brain. J. Alzheimers Dis. 2013;33:841-851.
Not in our library10.3233/jad-2012-121447
84.
Oz M., Lorke D.E., Yang K.H., Petroianu G. On the interaction of beta-amyloid peptides and alpha7-nicotinic acetylcholine receptors in Alzheimer’s disease. Curr. Alzheimer Res. 2013;10:618-630.
Not in our library10.2174/15672050113109990132
85.
Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246-260.
Not in our library10.1096/fj.06-7703com
86.
Xie L., Helmerhorst E., Taddei K., Plewright B., Van Bronswijk W., Martins R. Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002;22:RC221.
Not in our library10.1523/jneurosci.22-10-j0001.2002
87.
Boland K., Behrens M., Choi D., Manias K., Perlmutter D.H. The serpin-enzyme complex receptor recognizes soluble, nontoxic amyloid-beta peptide but not aggregated, cytotoxic amyloid-beta peptide. J. Biol. Chem. 1996;271:18032-18044.
Not in our library10.1074/jbc.271.30.18032
88.
Lai A.Y., McLaurin J. Mechanisms of amyloid-beta peptide uptake by neurons: The role of lipid rafts and lipid raft-associated proteins. Int. J. Alzheimers Dis. 2010;2011:548380.
Not in our library10.4061/2011/548380
89.
Zhao Y., Wu X., Li X., Jiang L.L., Gui X., Liu Y., Sun Y., Zhu B., Pina-Crespo J.C., Zhang M., et al. TREM2 is a receptor for beta-amyloid that mediates microglial function. Neuron. 2018;97:1023-1031.e7.
Not in our library10.1016/j.neuron.2018.01.031
90.
Hsieh C.L., Koike M., Spusta S.C., Niemi E.C., Yenari M., Nakamura M.C., Seaman W.E. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J. Neurochem. 2009;109:1144-1156.
Not in our library10.1111/j.1471-4159.2009.06042.x
91.
Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism · 2018
Corrected
92.
Wilhelmus M.M., Otte-Holler I., van Triel J.J., Veerhuis R., Maat-Schieman M.L., Bu G., de Waal R.M., Verbeek M.M. Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am. J. Pathol. 2007;171:1989-1999.
Not in our library10.2353/ajpath.2007.070050
93.
Saint-Pol J., Vandenhaute E., Boucau M.C., Candela P., Dehouck L., Cecchelli R., Dehouck M.P., Fenart L., Gosselet F. Brain pericytes ABCA1 expression mediates cholesterol efflux but not cellular amyloid-beta peptide accumulation. J. Alzheimers Dis. 2012;30:489-503.
Not in our library10.3233/jad-2012-112090
94.
Kuhnke D., Jedlitschky G., Grube M., Krohn M., Jucker M., Mosyagin I., Cascorbi I., Walker L.C., Kroemer H.K., Warzok R.W., et al. MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007;17:347-353.
Not in our library10.1111/j.1750-3639.2007.00075.x
95.
Rosenegger D.G., Tran C.H., Wamsteeker Cusulin J.I., Gordon G.R. Tonic local brain blood flow control by astrocytes independent of phasic neurovascular coupling. J. Neurosci. 2015;35:13463-13474.
Not in our library10.1523/jneurosci.1780-15.2015
96.
Carrano A., Hoozemans J.J., van der Vies S.M., van Horssen J., de Vries H.E., Rozemuller A.J. Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener. Dis. 2012;10:329-331.
Not in our library10.1159/000334916
97.
Lymphatic Clearance of the Brain: Perivascular, Paravascular and Significance for Neurodegenerative Diseases · 2016
No notice
98.
Rasmussen M.K., Mestre H., Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018;17:1016-1024.
Not in our library10.1016/s1474-4422(18)30318-1
99.
Ulv Larsen S.M., Landolt H.P., Berger W., Nedergaard M., Knudsen G.M., Holst S.C. Haplotype of the astrocytic water channel AQP4 is associated with slow wave energy regulation in human NREM sleep. PLoS Biol. 2020;18:e3000623.
Not in our library10.1371/journal.pbio.3000623
100.
Burfeind K.G., Murchison C.F., Westaway S.K., Simon M.J., Erten-Lyons D., Kaye J.A., Quinn J.F., Iliff J.J. The effects of noncoding aquaporin-4 single-nucleotide polymorphisms on cognition and functional progression of Alzheimer’s disease. Alzheimers Dement. (NY). 2017;3:348-359.
Not in our library10.1016/j.trci.2017.05.001
101.
Zeppenfeld D.M., Simon M., Haswell J.D., D’Abreo D., Murchison C., Quinn J.F., Grafe M.R., Woltjer R.L., Kaye J., Iliff J.J. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74:91-99.
Not in our library10.1001/jamaneurol.2016.4370
102.
Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409-427.
Not in our library10.1016/j.neuron.2010.09.043
103.
Alcendor D.J. Interactions between smyloid-beta proteins and human brain pericytes: Implications for the pathobiology of Alzheimer’s disease. J. Clin. Med. 2020;9:1490.
Not in our library10.3390/jcm9051490
104.
Nelson A.R., Sweeney M.D., Sagare A.P., Zlokovic B.V. Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer’s disease. Biochim. Biophys. Acta. 2016;1862:887-900.
Not in our library10.1016/j.bbadis.2015.12.016
105.
Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205-216.
Not in our library10.1016/s1474-4422(09)70016-x
106.
Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A., et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat. Med. 2005;11:959-965.
Not in our library10.1038/nm1287
107.
Ogunshola O.O., Antoniou X. Contribution of hypoxia to Alzheimer’s disease: Is HIF-1alpha a mediator of neurodegeneration? Cell Mol. Life Sci. 2009;66:3555-3563.
Not in our library10.1007/s00018-009-0141-0
108.
Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer’s disease. Nat. Rev. Neurosci. 2004;5:347-360.
Not in our library10.1038/nrn1387
109.
Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80:844-866.
Not in our library10.1016/j.neuron.2013.10.008
110.
Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330:1774.
Not in our library10.1126/science.1197623
111.
Tarasoff-Conway J.M., Carare R.O., Osorio R.S., Glodzik L., Butler T., Fieremans E., Axel L., Rusinek H., Nicholson C., Zlokovic B.V., et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 2015;11:457-470.
Not in our library10.1038/nrneurol.2015.119
112.
Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., et al. RAGE, LRP-1, and amyloid-beta protein in Alzheimer’s disease. Acta Neuropathol. 2006;112:405-415.
Not in our library10.1007/s00401-006-0115-3
113.
Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 2009;11:143-153.
Not in our library10.1038/ncb1819
114.
Sagare A.P., Bell R.D., Zlokovic B.V. Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012;2:a011452.
Not in our library10.1101/cshperspect.a011452
115.
Deane R., Singh I., Sagare A.P., Bell R.D., Ross N.T., LaRue B., Love R., Perry S., Paquette N., Deane R.J., et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-mediated brain disorder in a mouse model of Alzheimer disease. J. Clin. Investig. 2012;122:1377-1392.
Not in our library10.1172/jci58642
116.
Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s Disease · 2012
No notice
117.
Li J.M., Huang L.L., Liu F., Tang B.S., Yan X.X. Can brain impermeable BACE1 inhibitors serve as anti-CAA medicine? BMC Neurol. 2017;17:163.
Not in our library10.1186/s12883-017-0942-y
118.
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease · 2014
No notice
119.
Chris Min K., Dockendorf M.F., Palcza J., Tseng J., Ma L., Stone J.A., Kleijn H.J., Hodsman P., Masuo K., Tanen M., et al. Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor verubecestat (MK-8931) in healthy Japanese adults: A randomized, placebo-controlled study. Clin. Pharmacol. Ther. 2019;105:1234-1243.
Not in our library10.1002/cpt.1258
120.
Vandenberghe R., Riviere M.E., Caputo A., Sovago J., Maguire R.P., Farlow M., Marotta G., Sanchez-Valle R., Scheltens P., Ryan J.M., et al. Active Abeta immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study. Alzheimers Dement. (NY). 2017;3:10-22.
Not in our library10.1016/j.trci.2016.12.003
121.
Folch J., Ettcheto M., Petrov D., Abad S., Pedros I., Marin M., Olloquequi J., Camins A. Review of the advances in treatment for Alzheimer disease: Strategies for combating beta-amyloid protein. Neurologia. 2018;33:47-58.
Not in our library10.1016/j.nrl.2015.03.012
122.
Veeraraghavalu K., Zhang C., Zhang X., Tanzi R.E., Sisodia S.S. Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of beta-amyloid by cells other than excitatory neurons. J. Neurosci. 2014;34:3668-3673.
Not in our library10.1523/jneurosci.5079-13.2014
123.
Henley D.B., May P.C., Dean R.A., Siemers E.R. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer’s disease. Expert Opin. Pharmacother. 2009;10:1657-1664.
Not in our library10.1517/14656560903044982
124.
Coric V., Salloway S., van Dyck C.H., Dubois B., Andreasen N., Brody M., Curtis C., Soininen H., Thein S., Shiovitz T., et al. Targeting prodromal Alzheimer disease with avagacestat: A randomized clinical trial. JAMA Neurol. 2015;72:1324-1333.
Not in our library10.1001/jamaneurol.2015.0607
125.
Wu Y., Cui J. (-)-Epigallocatechin-3-gallate provides neuroprotection via AMPK activation against traumatic brain injury in a mouse model. Naunyn Schmiedebergs Arch. Pharmacol. 2020;393:2209-2220.
Not in our library10.1007/s00210-020-01841-1
126.
Mori T., Koyama N., Tan J., Segawa T., Maeda M., Town T. Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. J. Biol. Chem. 2019;294:2714-2731.
Not in our library10.1074/jbc.ra118.004280
127.
Raghuvanshi R., Bharate S.B. Preclinical and clinical studies on bryostatins, a class of marine-derived protein kinase C modulators: A mini-review. Curr. Top Med. Chem. 2020;20:1124-1135.
Not in our library10.2174/1568026620666200325110444
128.
Yiannopoulou K.G., Papageorgiou S.G. Current and future treatments in Alzheimer disease: An update. J. Cent. Nerv. Syst. Dis. 2020;12.
Not in our library10.1177/1179573520907397
129.
Talaga P. Beta-amyloid aggregation inhibitors for the treatment of Alzheimer’s disease: Dream or reality? Mini Rev. Med. Chem. 2001;1:175-186.
Not in our library10.2174/1389557013407098
130.
Santa-Maria I., Hernandez F., Del Rio J., Moreno F.J., Avila J. Tramiprosate, a drug of potential interest for the treatment of Alzheimer’s disease, promotes an abnormal aggregation of tau. Mol. Neurodegener. 2007;2:17.
Not in our library10.1186/1750-1326-2-17
131.
Sabbagh M.N., Agro A., Bell J., Aisen P.S., Schweizer E., Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2011;25:206-212.
Not in our library10.1097/wad.0b013e318204b550
132.
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment · 2016
No notice
133.
An Overview on the Clinical Development of Tau-Based Therapeutics · 2018
No notice
134.
Turner R.S., Hebron M.L., Lawler A., Mundel E.E., Yusuf N., Starr J.N., Anjum M., Pagan F., Torres-Yaghi Y., Shi W., et al. Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer’s disease. Ann. Neurol. 2020;88:183-194.
Not in our library10.1002/ana.25775
135.
Pasquier F., Sadowsky C., Holstein A., Leterme Gle P., Peng Y., Jackson N., Fox N.C., Ketter N., Liu E., Ryan J.M., et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer’s disease. J. Alzheimers Dis. 2016;51:1131-1143.
Not in our library10.3233/jad-150376
136.
Harigaya Y., Saido T.C., Eckman C.B., Prada C.M., Shoji M., Younkin S.G. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer’s disease brain. Biochem. Biophys. Res. Commun. 2000;276:422-427.
Not in our library10.1006/bbrc.2000.3490
137.
Pike C.J., Overman M.J., Cotman C.W. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995;270:23895-23898.
Not in our library10.1074/jbc.270.41.23895
138.
Wilcock D.M., Colton C.A. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol. Disord. Drug Targets. 2009;8:50-64.
Not in our library10.2174/187152709787601858
139.
Budd Haeberlein S., O’Gorman J., Chiao P., Bussiere T., von Rosenstiel P., Tian Y., Zhu Y., von Hehn C., Gheuens S., Skordos L., et al. Clinical development of aducanumab, an anti-Abeta human monoclonal antibody being investigated for the treatment of early Alzheimer’s disease. J. Prev. Alzheimers Dis. 2017;4:255-263.
Not in our library10.14283/jpad.2017.39
140.
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice · 2020
Not checked
141.
Samadi H., Sultzer D. Solanezumab for Alzheimer’s disease. Expert Opin. Biol. Ther. 2011;11:787-798.
Not in our library10.1517/14712598.2011.578573
142.
Yang T., Dang Y., Ostaszewski B., Mengel D., Steffen V., Rabe C., Bittner T., Walsh D.M., Selkoe D.J. Target engagement in an alzheimer trial: Crenezumab lowers amyloid beta oligomers in cerebrospinal fluid. Ann. Neurol. 2019;86:215-224.
Not in our library10.1002/ana.25513
143.
Pradier L., Blanchard-Bregeon V., Bohme A., Debeir T., Menager J., Benoit P., Barneoud P., Taupin V., Bertrand P., Dugay P., et al. SAR228810: An antibody for protofibrillar amyloid beta peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). Alzheimers. Res. Ther. 2018;10:117.
Not in our library10.1186/s13195-018-0447-y
144.
Andreasen N., Simeoni M., Ostlund H., Lisjo P.I., Fladby T., Loercher A.E., Byrne G.J., Murray F., Scott-Stevens P.T., Wallin A., et al. First administration of the Fc-attenuated anti-beta amyloid antibody GSK933776 to patients with mild Alzheimer’s disease: A randomized, placebo-controlled study. PLoS ONE. 2015;10:e0098153.
Not in our library10.1371/journal.pone.0098153
145.
Landen J.W., Andreasen N., Cronenberger C.L., Schwartz P.F., Borjesson-Hanson A., Ostlund H., Sattler C.A., Binneman B., Bednar M.M. Ponezumab in mild-to-moderate Alzheimer’s disease: Randomized phase II PET-PIB study. Alzheimers Dement. (NY). 2017;3:393-401.
Not in our library10.1016/j.trci.2017.05.003
146.
Sollvander S., Nikitidou E., Gallasch L., Zysk M., Soderberg L., Sehlin D., Lannfelt L., Erlandsson A. The Abeta protofibril selective antibody mAb158 prevents accumulation of Abeta in astrocytes and rescues neurons from Abeta-induced cell death. J. Neuroinflamm. 2018;15:98.
Not in our library10.1186/s12974-018-1134-4
147.
Loeffler D.A. Intravenous immunoglobulin and Alzheimer’s disease: What now? J. Neuroinflamm. 2013;10:70.
Not in our library10.1186/1742-2094-10-70
148.
Sano M. Tarenflurbil: Mechanisms and myths. Arch. Neurol. 2010;67:750-752.
Not in our library10.1001/archneurol.2010.94
149.
Sivilia S., Lorenzini L., Giuliani A., Gusciglio M., Fernandez M., Baldassarro V.A., Mangano C., Ferraro L., Pietrini V., Baroc M.F., et al. Multi-target action of the novel anti-Alzheimer compound CHF5074: In vivo study of long term treatment in Tg2576 mice. BMC Neurosci. 2013;14:44.
Not in our library10.1186/1471-2202-14-44
150.
Wijesuriya H.C., Bullock J.Y., Faull R.L., Hladky S.B., Barrand M.A. ABC efflux transporters in brain vasculature of Alzheimer’s subjects. Brain Res. 2010;1358:228-238.
Not in our library10.1016/j.brainres.2010.08.034
151.
Ghose A.K., Viswanadhan V.N., Wendoloski J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1999;1:55-68.
Not in our library10.1021/cc9800071
152.
Pardridge W.M. Molecular Trojan horses for blood-brain barrier drug delivery. Discov. Med. 2006;6:139-143.
Not in our library10.1016/j.coph.2006.06.001
153.
Park K. Drug delivery of the future: Chasing the invisible gorilla. J. Control. Release. 2016;240:2-8.
Not in our library10.1016/j.jconrel.2015.10.048
154.
Saraiva C., Praca C., Ferreira R., Santos T., Ferreira L., Bernardino L. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J. Control. Release. 2016;235:34-47.
Not in our library10.1016/j.jconrel.2016.05.044
155.
Ramalho M.J., Andrade S., Loureiro J.A., do Carmo Pereira M. Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds. Drug Deliv. Transl. Res. 2020;10:380-402.
Not in our library10.1007/s13346-019-00694-3
156.
Kim M.H., Maeng H.J., Yu K.H., Lee K.R., Tsuruo T., Kim D.D., Shim C.K., Chung S.J. Evidence of carrier-mediated transport in the penetration of donepezil into the rat brain. J. Pharm. Sci. 2010;99:1548-1566.
Not in our library10.1002/jps.21895
157.
Brousseau G., Rourke B.P., Burke B. Acetylcholinesterase inhibitors, neuropsychiatric symptoms, and Alzheimer’s disease subtypes: An alternate hypothesis to global cognitive enhancement. Exp. Clin. Psychopharmacol. 2007;15:546-554.
Not in our library10.1037/1064-1297.15.6.546
158.
Ishiwata K., Kawamura K., Yanai K., Hendrikse N.H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med. 2007;48:81-87.
Not in our library
159.
Scheff S.W., Price D.A., Schmitt F.A., Mufson E.J. Hippocampal synaptic loss in early Alzheimer’s disease and mild cognitive impairment. Neurobiol. Aging. 2006;27:1372-1384.
Not in our library10.1016/j.neurobiolaging.2005.09.012
160.
Dong Y., Li X., Cheng J., Hou L. Drug development for Alzheimer’s disease: Microglia induced neuroinflammation as a target? Int. J. Mol. Sci. 2019;20:558.
Not in our library10.3390/ijms20030558
161.
Golde T.E., Koo E.H., Felsenstein K.M., Osborne B.A., Miele L. gamma-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 2013;1828:2898-2907.
Not in our library10.1016/j.bbamem.2013.06.005
162.
Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
Not in our library10.1212/01.wnl.0000159740.16984.3c
163.
Immunotherapy for Alzheimer’s disease: hoops and hurdles · 2013
No notice
164.
DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA. 2001;98:8850-8855.
Not in our library10.1073/pnas.151261398
165.
Banks W.A., Pagliari P., Nakaoke R., Morley J.E. Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins. Peptides. 2005;26:287-294.
Not in our library10.1016/j.peptides.2004.09.016
166.
Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., Morley J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer’s disease. Peptides. 2002;23:2223-2226.
Not in our library10.1016/s0196-9781(02)00261-9
167.
Poduslo J.F., Curran G.L., Berg C.T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA. 1994;91:5705-5709.
Not in our library10.1073/pnas.91.12.5705
168.
Kozlowski G.P., Sterzl I., Nilaver G. Localization patterns for immunoglobulins and albumins in the brain suggest diverse mechanisms for their transport across the blood-brain barrier (BBB). Prog. Brain Res. 1992;91:149-154.
Not in our library10.1016/s0079-6123(08)62329-8
169.
Banks W.A. Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des. 2004;10:1365-1370.
Not in our library10.2174/1381612043384862
170.
Schlachetzki F., Zhu C., Pardridge W.M. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J. Neurochem. 2002;81:203-206.
Not in our library10.1046/j.1471-4159.2002.00840.x
171.
Wischik C.M., Edwards P.C., Lai R.Y., Roth M., Harrington C.R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl. Acad. Sci. USA. 1996;93:11213-11218.
Not in our library10.1073/pnas.93.20.11213
172.
Melis V., Magbagbeolu M., Rickard J.E., Horsley D., Davidson K., Harrington K.A., Goatman K., Goatman E.A., Deiana S., Close S.P., et al. Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav. Pharmacol. 2015;26:353-368.
Not in our library10.1097/fbp.0000000000000133
173.
Congdon E.E., Sigurdsson E.M. Tau-targeting therapies for Alzheimer disease. Nat. Rev. Neurol. 2018;14:399-415.
Not in our library10.1038/s41582-018-0013-z
174.
Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007;27:9115-9129.
Not in our library10.1523/jneurosci.2361-07.2007
175.
Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011;118:658-667.
Not in our library10.1111/j.1471-4159.2011.07337.x
176.
Kfoury N., Holmes B.B., Jiang H., Holtzman D.M., Diamond M.I. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 2012;287:19440-19451.
Not in our library10.1074/jbc.m112.346072
177.
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model · 2014
No notice
178.
Breitner J.C., Haneuse S.J., Walker R., Dublin S., Crane P.K., Gray S.L., Larson E.B. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72:1899-1905.
Not in our library10.1212/wnl.0b013e3181a18691
179.
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models · 2016
No notice
180.
Wang J., Tan L., Wang H.F., Tan C.C., Meng X.F., Wang C., Tang S.W., Yu J.T. Anti-inflammatory drugs and risk of Alzheimer’s disease: An updated systematic review and meta-analysis. J. Alzheimers Dis. 2015;44:385-396.
Not in our library10.3233/jad-141506
181.
Akinyemi R.O., Mukaetova-Ladinska E.B., Attems J., Ihara M., Kalaria R.N. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer’s disease and vascular dementia. Curr. Alzheimer Res. 2013;10:642-653.
Not in our library10.2174/15672050113109990037
182.
Sebastiao I., Candeias E., Santos M.S., de Oliveira C.R., Moreira P.I., Duarte A.I. Insulin as a bridge between yype 2 diabetes and Alzheimer disease—how anti-diabetics could be a solution for dementia. Front. Endocrinol. (Lausanne). 2014;5:110.
Not in our library10.3389/fendo.2014.00110
183.
Fernandez A.M., Torres-Aleman I. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 2012;13:225-239.
Not in our library10.1038/nrn3209
184.
Hughes T.M., Craft S. The role of insulin in the vascular contributions to age-related dementia. Biochim. Biophys. Acta. 2016;1862:983-991.
Not in our library10.1016/j.bbadis.2015.11.013
185.
Barazzoni R., Zanetti M., Gortan Cappellari G., Semolic A., Boschelle M., Codarin E., Pirulli A., Cattin L., Guarnieri G. Fatty acids acutely enhance insulin-induced oxidative stress and cause insulin resistance by increasing mitochondrial reactive oxygen species (ROS) generation and nuclear factor-kappaB inhibitor (IkappaB)-nuclear factor-kappaB (NFkappaB) activation in rat muscle, in the absence of mitochondrial dysfunction. Diabetologia. 2012;55:773-782.
Not in our library10.1007/s00125-011-2396-x
186.
Cersosimo E., DeFronzo R.A. Insulin resistance and endothelial dysfunction: The road map to cardiovascular diseases. Diabetes Metab. Res. Rev. 2006;22:423-436.
Not in our library10.1002/dmrr.634
187.
Bhat N.R. Vasculoprotection as a convergent, multi-targeted mechanism of anti-AD therapeutics and interventions. J. Alzheimers Dis. 2015;46:581-591.
Not in our library10.3233/jad-150098
188.
Microglial Activation Is Modulated by Captopril: in Vitro and in Vivo Studies · 2018
Not checked
189.
Ongali B., Nicolakakis N., Tong X.K., Aboulkassim T., Papadopoulos P., Rosa-Neto P., Lecrux C., Imboden H., Hamel E. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol. Dis. 2014;68:126-136.
Not in our library10.1016/j.nbd.2014.04.018
190.
Anekonda T.S., Quinn J.F. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: The case for isradipine. Biochim. Biophys. Acta. 2011;1812:1584-1590.
Not in our library10.1016/j.bbadis.2011.08.013
191.
Yildirim Simsir I., Soyaltin U.E., Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer’s disease. Diabetes Metab. Syndr. 2018;12:469-475.
Not in our library10.1016/j.dsx.2018.03.002
192.
Burns D.K., Chiang C., Welsh-Bohmer K.A., Brannan S.K., Culp M., O’Neil J., Runyan G., Harrigan P., Plassman B.L., Lutz M., et al. The TOMMORROW study: Design of an Alzheimer’s disease delay-of-onset clinical trial. Alzheimers Dement. (NY). 2019;5:661-670.
Not in our library10.1016/j.trci.2019.09.010
193.
Miller B.W., Willett K.C., Desilets A.R. Rosiglitazone and pioglitazone for the treatment of Alzheimer’s disease. Ann. Pharmacother. 2011;45:1416-1424.
Not in our library10.1345/aph.1q238
194.
Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch. Neurol. 2012;69:29-38.
Not in our library10.1001/archneurol.2011.233
195.
Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease · 2017
No notice
196.
Simons M., Schwarzler F., Lutjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 2002;52:346-350.
Not in our library10.1002/ana.10292
197.
Manocha G., Ghatak A., Puig K., Combs C. Anti-alpha4beta1 integrin antibodies attenuated brain inflammatory changes in a mouse model of Alzheimer’s disease. Curr. Alzheimer Res. 2018;15:1123-1135.
Not in our library10.2174/1567205015666180801111033
198.
Cavalli G., Dinarello C.A. Corrigendum: Anakinra therapy for non-cancer inflammatory diseases. Front. Pharmacol. 2019;10:148.
Not in our library10.3389/fphar.2019.00148
199.
Budni J., Bellettini-Santos T., Mina F., Garcez M.L., Zugno A.I. The involvement of BDNF, NGF and GDNF in aging and Alzheimer’s disease. Aging Dis. 2015;6:331-341.
Not in our library10.14336/ad.2015.0825
200.
Revilla S., Ursulet S., Alvarez-Lopez M.J., Castro-Freire M., Perpina U., Garcia-Mesa Y., Bortolozzi A., Gimenez-Llort L., Kaliman P., Cristofol R., et al. Lenti-GDNF gene therapy protects against Alzheimer’s disease-like neuropathology in 3xTg-AD mice and MC65 cells. CNS Neurosci. Ther. 2014;20:961-972.
Not in our library10.1111/cns.12312
201.
Harris R., Miners J.S., Allen S., Love S. VEGFR1 and VEGFR2 in Alzheimer’s Disease. J. Alzheimers Dis. 2018;61:741-752.
Not in our library10.3233/jad-170745
202.
Religa P., Cao R., Religa D., Xue Y., Bogdanovic N., Westaway D., Marti H.H., Winblad B., Cao Y. VEGF significantly restores impaired memory behavior in Alzheimer’s mice by improvement of vascular survival. Sci. Rep. 2013;3:2053.
Not in our library10.1038/srep02053
203.
Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF · 2019
No notice
204.
Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008;28:9287-9296.
Not in our library10.1523/jneurosci.3348-08.2008
205.
Zolezzi J.M., Bastias-Candia S., Santos M.J., Inestrosa N.C. Alzheimer’s disease: Relevant molecular and physiopathological events affecting amyloid-beta brain balance and the putative role of PPARs. Front. Aging Neurosci. 2014;6:176.
Not in our library10.3389/fnagi.2014.00176
206.
Papadopoulos P., Rosa-Neto P., Rochford J., Hamel E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer’s disease with combined amyloid-beta and cerebrovascular pathology. PLoS ONE. 2013;8:e68612.
Not in our library10.1371/journal.pone.0068612
207.
Tong X.K., Lecrux C., Rosa-Neto P., Hamel E. Age-dependent rescue by simvastatin of Alzheimer’s disease cerebrovascular and memory deficits. J. Neurosci. 2012;32:4705-4715.
Not in our library10.1523/jneurosci.0169-12.2012
208.
Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation · 2019
No notice
209.
Nimmrich V., Eckert A. Calcium channel blockers and dementia. Br. J. Pharmacol. 2013;169:1203-1210.
Not in our library10.1111/bph.12240
210.
Saavedra J.M. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. (Lond.). 2012;123:567-590.
Not in our library10.1042/cs20120078
211.
Folch J., Busquets O., Ettcheto M., Sanchez-Lopez E., Castro-Torres R.D., Verdaguer E., Garcia M.L., Olloquequi J., Casadesus G., Beas-Zarate C., et al. Memantine for the treatment of dementia: A review on its current and future Applications. J. Alzheimers Dis. 2018;62:1223-1240.
Not in our library10.3233/jad-170672
212.
Chen Z.Z., Yang D.D., Zhao Z., Yan H., Ji J., Sun X.L. Memantine mediates neuroprotection via regulating neurovascular unit in a mouse model of focal cerebral ischemia. Life Sci. 2016;150:8-14.
Not in our library10.1016/j.lfs.2016.02.081
213.
Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002;200:629-638.
Not in our library10.1046/j.1469-7580.2002.00064.x
214.
Nagelhus E.A., Mathiisen T.M., Ottersen O.P. Aquaporin-4 in the central nervous system: Cellular and subcellular distribution and coexpression with KIR4.1. Neuroscience. 2004;129:905-913.
Not in our library10.1016/j.neuroscience.2004.08.053
215.
Wang X., Rosell A., Lo E.H. Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy. CNS Neurol. Disord. Drug Targets. 2008;7:235-242.
Not in our library10.2174/187152708784936635
216.
Blamire A.M., Anthony D.C., Rajagopalan B., Sibson N.R., Perry V.H., Styles P. Interleukin-1beta -induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: A magnetic resonance study. J. Neurosci. 2000;20:8153-8159.
Not in our library10.1523/jneurosci.20-21-08153.2000
217.
Kary S., Burmester G.R. Anakinra: The first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int. J. Clin. Pract. 2003;57:231-234.
Not in our library
218.
Hue C.D., Cho F.S., Cao S., Dale Bass C.R., Meaney D.F., Morrison B. Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein. J. Cereb. Blood Flow Metab. 2015;35:1191-1198.
Not in our library10.1038/jcbfm.2015.38
219.
Engelhardt B., Kappos L. Natalizumab: Targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 2008;5:16-22.
Not in our library10.1159/000109933
220.
Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol. 2009;118:103-113.
Not in our library10.1007/s00401-009-0522-3
221.
DiSabato D.J., Quan N., Godbout J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016;139:136-153.
Not in our library10.1111/jnc.13607
222.
Xiong X.Y., Liu L., Yang Q.W. Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke. Prog. Neurobiol. 2016;142:23-44.
Not in our library10.1016/j.pneurobio.2016.05.001
223.
Zamanian J.L., Xu L., Foo L.C., Nouri N., Zhou L., Giffard R.G., Barres B.A. Genomic analysis of reactive astrogliosis. J. Neurosci. 2012;32:6391-6410.
Not in our library10.1523/jneurosci.6221-11.2012
224.
Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Munch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481-487.
Not in our library10.1038/nature21029
225.
Boado R.J., Hui E.K., Lu J.Z., Zhou Q.H., Pardridge W.M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 2010;146:84-91.
Not in our library10.1016/j.jbiotec.2010.01.011
226.
Koo Y.E., Reddy G.R., Bhojani M., Schneider R., Philbert M.A., Rehemtulla A., Ross B.D., Kopelman R. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Deliv. Rev. 2006;58:1556-1577.
Not in our library10.1016/j.addr.2006.09.012
227.
Dadparvar M., Wagner S., Wien S., Kufleitner J., Worek F., von Briesen H., Kreuter J. HI 6 human serum albumin nanoparticles--development and transport over an in vitro blood-brain barrier model. Toxicol. Lett. 2011;206:60-66.
Not in our library10.1016/j.toxlet.2011.06.027
228.
Andrade S., Ramalho M.J., Loureiro J.A., Pereira M.C. Interaction of natural compounds with biomembrane models: A biophysical approach for the Alzheimer’s disease therapy. Coll. Surf. B Biointerfaces. 2019;180:83-92.
Not in our library10.1016/j.colsurfb.2019.04.019
229.
Surnar B., Basu U., Banik B., Ahmad A., Marples B., Kolishetti N., Dhar S. Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection. Proc. Natl. Acad. Sci. USA. 2018;115:E12333-E12342.
Not in our library10.1073/pnas.1816429115
230.
Liu X., Ye M., An C., Pan L., Ji L. The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia. Biomaterials. 2013;34:6893-6905.
Not in our library10.1016/j.biomaterials.2013.05.021
231.
Liu X., An C., Jin P., Liu X., Wang L. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials. 2013;34:817-830.
Not in our library10.1016/j.biomaterials.2012.10.017
232.
Karatas H., Aktas Y., Gursoy-Ozdemir Y., Bodur E., Yemisci M., Caban S., Vural A., Pinarbasli O., Capan Y., Fernandez-Megia E., et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J. Neurosci. 2009;29:13761-13769.
Not in our library10.1523/jneurosci.4246-09.2009
233.
Neurovascular dysfunction, inflammation and endothelial activation: Implications for the pathogenesis of Alzheimer's disease · 2011
No notice
234.
Ross C., Taylor M., Fullwood N., Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int. J. Nanomed. 2018;13:8507-8522.
Not in our library10.2147/ijn.s183117
235.
Vangilder R.L., Rosen C.L., Barr T.L., Huber J.D. Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol. Ther. 2011;130:239-247.
Not in our library10.1016/j.pharmthera.2010.12.004
236.
Joshi S., Singh-Moon R.P., Ellis J.A., Chaudhuri D.B., Wang M., Reif R., Bruce J.N., Bigio I.J., Straubinger R.M. Cerebral hypoperfusion-assisted intra-arterial deposition of liposomes in normal and glioma-bearing rats. Neurosurgery. 2015;76:92-100.
Not in our library10.1227/neu.0000000000000552

Cited by papers we hold 4

Alzheimer’s Disease: An Updated Overview of Its Genetics · 2023
No notice
The “Neuro-Glial-Vascular” Unit: The Role of Glia in Neurovascular Unit Formation and Dysfunction · 2021
No notice
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease · 2021
No notice
Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.